HUE027953T2 - A gyökfogó és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása - Google Patents

A gyökfogó és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása Download PDF

Info

Publication number
HUE027953T2
HUE027953T2 HUE09777272A HUE09777272A HUE027953T2 HU E027953 T2 HUE027953 T2 HU E027953T2 HU E09777272 A HUE09777272 A HU E09777272A HU E09777272 A HUE09777272 A HU E09777272A HU E027953 T2 HUE027953 T2 HU E027953T2
Authority
HU
Hungary
Prior art keywords
alpha
cells
heme
haemoglobin
blood
Prior art date
Application number
HUE09777272A
Other languages
English (en)
Inventor
Bo Akerstroem
Stefan Hansson
Martin Lennarth Olsson
Magnus Gram
Original Assignee
A1M Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A1M Pharma Ab filed Critical A1M Pharma Ab
Publication of HUE027953T2 publication Critical patent/HUE027953T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)

Claims (9)

  1. CLAIMS 1. 1, Alfa-i-míkrogíobulin oxidativ stresszel j<*r0 betegseg vagy állapot kezdésében vagy magdozésében történő oxidativ károseoasnafe enzimatikus redakcíé, |#.»^ÄiÄus redukció «s gyokrogás kom·» . .bid-ác^jávai történd '|á'«\ésévál vagy megelőzlek'' s felétdid, hogy az állapot vagy betegség wn praedámpsiá.
  2. 2. Álfa-'l-imikrogiobisllo az i, igénypont szeri nd aikaímazasra, ahol a betegség vagy álladót szabad dsmogíoblansk agy tasttoipdakbap cMshő jelenlétével függ össze.
  3. 3. Alfa-l-mikreglübullo az 1. vagy 2. igénygotk szőri ott alkalmazásra, mely legalább 6ö%~ban azonos; a búmén afa^-míkröglobtflion®! (L számú szekvencia)1.
  4. 4. Alfa-i-'mlikfogíobulin az előző igényponti bármelyike szerinti alkalmazásra, aho l az alta-i-mskrogiobullrs humán aitdre-mskroglöbulín (1. számú szekvencia).
  5. 5. AIM-1-mlkböpÄjifc az t-1, Igénypontok bármelyike szerint! alkalmazásra, áhöl az alfa-®$%~báh M&amp;im&amp; a búmén tekom-bináns alfa-t-rniikrogiobuiinnal (2, számú szekvendb),
  6. 6. Alfa -1. - m i k rog l o b u írn az if % S, Igénypontok bármelyike szerinti alk kaimazásra, ahoi az alfa·· 1 -mikrogiohulin humán rakomöináns alfa-!-Mikroglöbulln :(2. számé szekvencia;},
  7. 7. Aiap-nzikrogiobuko az 1-6. Igénypontok bármelyike szerinti ai-kaimazásra, ahol az aifa-l -mikrogiobukot pareoter#lsan adagoljuk.
  8. 8. Aifa-Z'-mikmglgfealjn az 7-6, Igénypontok bármelyike szerinti alkalmazásra, ahol az alp-l-mlkreglöádllbt. lokálisam például e§y testüregben vagy a bőrre adagoljuk.
  9. 9.. Álfa* l-mikroglobufio az előző igénypontok bármelyike szerinti alkalmazásra, ahol az alfa-l-mskroglobulint alfa* i-mikrcgíobullnt és egy gyógyszerészetHeg elfogadható adalékanyagot tartalmazó készítményként adagoltuk, iö. Alfa-l-mikrogfohulln a 9. igénypont szerinti alkalmazásra, ahol a gyógyászatiig elfogadható adalékanyag oldószerek, pH-beáüitó szerek, ozmózis* aktív szerek, koszol versek, szoiubilizáió szerek, emulgealószerek, szoszpendálószerek, felületaktív szerek, nedvesítoszerek, stb. közül választott.
HUE09777272A 2008-07-18 2009-07-17 A gyökfogó és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása HUE027953T2 (hu)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13533808P 2008-07-18 2008-07-18
DKPA200801024 2008-07-18
US18938108P 2008-08-18 2008-08-18
DKPA200801116 2008-08-18
US19750608P 2008-10-27 2008-10-27
DKPA200801478 2008-10-27

Publications (1)

Publication Number Publication Date
HUE027953T2 true HUE027953T2 (hu) 2017-01-30

Family

ID=41550762

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE09777272A HUE027953T2 (hu) 2008-07-18 2009-07-17 A gyökfogó és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása
HUE13172049A HUE030274T2 (hu) 2008-07-18 2009-07-17 A gyökmegkötõ és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE13172049A HUE030274T2 (hu) 2008-07-18 2009-07-17 A gyökmegkötõ és antioxidáns alfa-1-mikroglobulin gyógyászati alkalmazása

Country Status (12)

Country Link
US (1) US10350268B2 (hu)
EP (2) EP2638915B1 (hu)
JP (3) JP5694928B2 (hu)
AU (1) AU2009270435B2 (hu)
CA (1) CA2730531A1 (hu)
DK (2) DK2313106T3 (hu)
ES (2) ES2571956T3 (hu)
HR (2) HRP20160760T1 (hu)
HU (2) HUE027953T2 (hu)
PL (2) PL2313106T3 (hu)
PT (1) PT2638915T (hu)
WO (1) WO2010006809A2 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5010920B2 (ja) 2003-11-08 2012-08-29 プロセラ・バイオロジクス 治療に使用するためのヒト血漿由来のインターα阻害タンパク質の調製方法及びその組成物
EA031877B1 (ru) 2007-02-12 2019-03-29 А1М Фарма Аб Применение альфа-1-микроглобулина для профилактики или лечения преэклампсии
CA2726281C (en) 2008-05-28 2023-04-18 Prothera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from blood
MX357656B (es) * 2012-09-05 2018-07-18 A1M Pharma Ab Alfa-1-microglobulina para usarse en tratamiento de enfermedades relacionadas a mitocondrias.
WO2014039987A2 (en) * 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
EP3102224B1 (en) * 2013-12-20 2019-02-20 NephroGenesis, LLC. Apparatuses for kidney dialysis and lipocalin protein for use in the prevention or treatment of uremia by dialysis
MX2018011193A (es) * 2016-03-18 2019-03-28 A1M Pharma Ab Proteinas derivadas de alfa-1-microglobulina novedosas y su uso.
WO2018094023A2 (en) * 2016-11-16 2018-05-24 Anand Prasad Cyclic dipeptides and wound healing
JP2021501750A (ja) * 2017-11-03 2021-01-21 ガード セラピューティクス インターナショナル エービーGuard Therapeutics International AB 骨髄細胞の保護のためのアルファ−1−ミクログロブリンの使用
JP6906807B2 (ja) * 2018-08-31 2021-07-21 一般社団法人クラインシュタイン医工学パースペクティブ 透析装置
WO2024165674A1 (en) 2023-02-08 2024-08-15 Guard Therapeutics International AB Alpha-1-microglobulin derived peptide fragments and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
US6103691A (en) * 1994-03-23 2000-08-15 Tschesche; Harald Utilisation of angiogenin and/or α1 -microglobulin and/or complement factor D in order to inhibit the secretion of proteins
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
JP2001348342A (ja) 2001-04-12 2001-12-18 Nippon Zoki Pharmaceut Co Ltd 免疫調整・抗炎症剤
DE10125883A1 (de) 2001-05-28 2002-12-12 Serumwerk Bernburg Ag Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
AR045074A1 (es) * 2003-07-23 2005-10-12 Applied Research Systems Uso de cd164 soluble en desordenes inflamatorios y autoinmunes
ITMI20032528A1 (it) 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US20060105419A1 (en) 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
JP2007001922A (ja) 2005-06-23 2007-01-11 Asahi Kasei Pharma Kk 透析患者における腎疾患改善剤、又は機能性食品
US20070292421A1 (en) 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
EA031877B1 (ru) * 2007-02-12 2019-03-29 А1М Фарма Аб Применение альфа-1-микроглобулина для профилактики или лечения преэклампсии

Also Published As

Publication number Publication date
JP2015071620A (ja) 2015-04-16
HRP20161808T1 (hr) 2017-02-24
ES2614490T3 (es) 2017-05-31
PL2313106T3 (pl) 2016-08-31
JP6406987B2 (ja) 2018-10-17
JP6175478B2 (ja) 2017-08-02
DK2638915T3 (en) 2017-01-30
WO2010006809A3 (en) 2010-05-27
PT2638915T (pt) 2017-01-10
ES2571956T3 (es) 2016-05-27
JP2012505154A (ja) 2012-03-01
HRP20160760T1 (hr) 2016-08-12
CA2730531A1 (en) 2010-01-21
WO2010006809A2 (en) 2010-01-21
US20110190208A1 (en) 2011-08-04
HUE030274T2 (hu) 2017-05-29
AU2009270435A1 (en) 2010-01-21
JP5694928B2 (ja) 2015-04-01
JP2016102125A (ja) 2016-06-02
EP2638915B1 (en) 2016-10-19
EP2313106A2 (en) 2011-04-27
US10350268B2 (en) 2019-07-16
AU2009270435B2 (en) 2014-10-16
DK2313106T3 (en) 2016-07-25
PL2638915T3 (pl) 2017-04-28
EP2638915A1 (en) 2013-09-18
EP2313106B1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
DK2313106T3 (en) MEDICAL USE OF RADICAL binder and the antioxidant is alpha-1-microglobulin
JP5685773B2 (ja) 血管新生および創傷治癒活性がある薬剤
JP2018203756A (ja) ミトコンドリア関連疾患の治療に使用するためのα−1−ミクログロブリン
Ebaid et al. Effect of STZ-induced diabetes on spleen of rats: improvement by camel whey proteins
KR20090033329A (ko) 가교된 헤모글로빈 혈액 대용품을 사용한 급성 혈액 손실 빈혈의 치료 방법
US20090291086A1 (en) Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
AU2014262273B2 (en) Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
JP2022533365A (ja) 出血性脳卒中後の有害な二次神経学的転帰を処置する際に使用するためのハプトグロビン
Sabapathy et al. The Yin and Yang of alarmins in regulation of acute kidney injury
CA2328134A1 (en) The induction of antibiotic proteins and peptides by lait/scd14-protein
CN105641688B (zh) C1抑制剂在预防缺血-再灌注损伤中的应用
McCormick et al. Clinically applicable thermal preconditioning attenuates leukocyte–endothelial interactions
RU2405558C2 (ru) Лекарственный препарат для лечения гипоксических и токсических митохондриальных нарушений и способ его получения
US20130165391A1 (en) B2-glycoprotein i peptide inhibitors
Televiak et al. Dynamic of indices of lipid peroxidation and antioxidant protection in muscular tissue and blood serum of rats with acute ischemia-reperfusion
Li et al. Kidney injury in a murine hemorrhagic shock/resuscitation model is alleviated by sulforaphane’s anti-inflammatory and antioxidant action
CA2625888A1 (en) Method of treating acute renal failure with thrombomodulin variant
Dobryszycka Haptoglobin in the new millenium
JP3569904B2 (ja) 臓器障害治療薬
WO2024023068A1 (en) Use of an annelid molecule for treating and/or preventing at least one complement-activation associated disease
Alotaibi et al. Evaluation of the Healing Effect of Cordycepin and Melittin in Experimentally-Induced Wounds in Diabetic Rats
JPH11349488A (ja) クラスタリンを含有する免疫抑制剤
WO2014205077A1 (en) Hemoglobin compositions